JPH089597B2
(ja)
*
|
1986-01-21 |
1996-01-31 |
杏林製薬株式会社 |
選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
|
FR2656611B1
(fr)
*
|
1990-01-04 |
1992-05-07 |
Hoechst France |
Nouvelles quinolones, leurs sels, utiles comme agents antimicrobiens, procede de preparation et leur application a titre de medicaments et compositions les renfermant.
|
FR2673426B1
(fr)
*
|
1991-03-01 |
1993-07-16 |
Bouchara Sa |
Nouvelles quinolones, leur procede de preparation et les compositions en refermant.
|
FR2674854B1
(fr)
*
|
1991-04-04 |
1995-03-03 |
Bouchara |
Nouvelles quinolones leur procede de preparation et les compositions pharmaceutiques en refermant.
|
FR2675144B1
(fr)
*
|
1991-04-10 |
1995-06-16 |
Bouchara Sa |
Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant.
|
EP0629621B1
(en)
*
|
1992-01-31 |
2001-10-24 |
Chugai Seiyaku Kabushiki Kaisha |
Crystal of quinolonecarboxylic acid derivative hydrate
|
WO1993022308A1
(en)
*
|
1992-04-28 |
1993-11-11 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing quinolonecarboxylic acid derivative
|
FR2692577B1
(fr)
*
|
1992-05-26 |
1996-02-02 |
Bouchara Sa |
Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant.
|
EP0726269B1
(en)
*
|
1993-10-28 |
2001-09-05 |
Kaken Pharmaceutical Co., Ltd. |
Quinolinecarboxylic acid derivatives and salts thereof
|
US5686095A
(en)
*
|
1995-10-23 |
1997-11-11 |
Price, Jr.; Francis W. |
Method of treating canker sores
|
ID24703A
(id)
*
|
1997-09-15 |
2000-08-03 |
Procter & Gamble |
Kuinolon antimikroba, komposisi dan penggunaannya
|
US6387928B1
(en)
*
|
1997-09-15 |
2002-05-14 |
The Procter & Gamble Co. |
Antimicrobial quinolones, their compositions and uses
|
DE19751948A1
(de)
*
|
1997-11-24 |
1999-05-27 |
Bayer Ag |
Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
|
US6608078B2
(en)
|
2000-05-08 |
2003-08-19 |
Wockhardt Limited |
Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
|
US7098219B2
(en)
|
2000-08-01 |
2006-08-29 |
Wockhart Limited |
Inhibitors of cellular efflux pumps of microbes
|
US6878713B2
(en)
|
2001-04-25 |
2005-04-12 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
US6964966B2
(en)
|
2001-04-25 |
2005-11-15 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
US7423153B2
(en)
*
|
2002-05-10 |
2008-09-09 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of gatifloxacin
|
WO2003099815A1
(en)
|
2002-05-28 |
2003-12-04 |
Wockhardt Limited |
Crystalline fluoroquinolone arginine salt form
|
US6900224B2
(en)
*
|
2002-07-31 |
2005-05-31 |
The Procter & Gamble Company |
Antimicrobial quinolones, their compositions and uses
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
DK1660495T3
(da)
|
2003-09-04 |
2007-11-05 |
Wockhardt Ltd |
Benzoquinolizin-2-carboxylsyreargininsalt,tetrahydrat
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
BRPI0709772B8
(pt)
|
2006-03-28 |
2021-05-25 |
The Protecter & Gamble Company |
sais de malato e polimorfos do ácido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-diidro-8-metóxi-4-oxo-3-quinolinocarboxílico
|
CA2647457C
(en)
*
|
2006-03-28 |
2011-05-24 |
The Procter & Gamble Company |
A hydride reduction process for preparing quinolone intermediates
|
US7456279B2
(en)
*
|
2006-03-28 |
2008-11-25 |
The Procter & Gamble Company |
Coupling process for preparing quinolone intermediates
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
TWI362386B
(en)
|
2007-03-30 |
2012-04-21 |
Daiichi Sankyo Co Ltd |
A production method for the qunolon-carboxylic acid derivative
|
CN101450938B
(zh)
*
|
2007-12-04 |
2012-11-14 |
中国医学科学院医药生物技术研究所 |
7-(4-肟基-3-氨基-3-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
KR20120107080A
(ko)
|
2009-11-27 |
2012-09-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
JP6034781B2
(ja)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
併用療法
|
AU2011268940B2
(en)
|
2010-06-24 |
2015-05-21 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
NZ618698A
(en)
|
2011-07-15 |
2015-08-28 |
Boehringer Ingelheim Int |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
CN103874514B
(zh)
|
2011-10-12 |
2017-04-12 |
优瑟夫·雅阿科比 |
隐形眼镜清洁系统
|
CN102558145B
(zh)
*
|
2011-12-14 |
2014-04-16 |
中国药科大学 |
巴洛沙星的制备方法
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
MX2018015089A
(es)
|
2016-06-10 |
2019-05-13 |
Boehringer Ingelheim Int |
Combinacion de linagliptina y metformina.
|